# Institut Jules Bordet

Source: https://onco.cc/institutions/institut-jules-bordet/  
OnCo record `institut-jules-bordet` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Belgium's only hospital devoted entirely to cancer, birthplace of the Breast International Group and a world centre for breast cancer trials.

## Summary

The Institut Jules Bordet opened in 1939, named after the Nobel laureate immunologist Jules Bordet, and moved to a new building beside Erasme Hospital in Anderlecht in 2021 as part of the Hôpital Universitaire de Bruxelles. It is OECI-accredited as a comprehensive cancer centre. Martine Piccart co-founded the Breast International Group here and led the HERA trial of adjuvant trastuzumab; Christos Sotiriou's laboratory developed gene expression signatures for breast cancer and Michail Ignatiadis leads circulating tumour DNA studies, while Ahmad Awada's early-phase unit tests new agents. Bordet is also strong in haematology, nuclear medicine and surgical oncology, and Brussels hosts both BIG and EORTC headquarters.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: Jules Bordet Institute; Bordet; Hôpital Universitaire de Bruxelles
- City: Brussels, BE
- Type: cancer-center
- Website: https://www.bordet.be

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Institut_Jules_Bordet
- Homepage: https://www.bordet.be
- Breast International Group: https://www.bigagainstbreastcancer.org

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Endocrine therapy (SERMs, AIs, SERDs)](https://onco.cc/technologies/endocrine-therapy/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [RNA sequencing & expression profiling](https://onco.cc/technologies/rna-seq/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- companies: [Breast International Group (BIG)](https://onco.cc/companies/big/), [EORTC](https://onco.cc/companies/curie-nki-eortc/)
- institutions: [King Albert II Cancer Institute, Cliniques universitaires Saint-Luc](https://onco.cc/institutions/king-albert-ii-cancer-institute/), [Organisation of European Cancer Institutes](https://onco.cc/institutions/oeci/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/)
- people: [Evandro de Azambuja](https://onco.cc/people/evandro-de-azambuja/), [Martine Piccart](https://onco.cc/people/martine-piccart/), [Renaud Witmeur](https://onco.cc/people/renaud-witmeur/), [Sacha Gougnard](https://onco.cc/people/sacha-gougnard/)
- key papers: [Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features](https://onco.cc/key-papers/paper-puleo-pancreatic-tumour-microenvironment-subtypes-gastroenterology-2018/), [Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach](https://onco.cc/key-papers/paper-bareche-tnbc-microenvironment-jnci-2020/), [Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis](https://onco.cc/key-papers/paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018/)

---
JSON: https://onco.cc/api/v1/entities/institut-jules-bordet.json